In Vivo Hyperglycemic Effect of (−)- and (+)-Epinephrine in Dogs
(−)-Epinephrine is a major component in the regulation of the physiological homeostasis of glucose levels in the blood. (+)-Epinephrine, a synthetic stereoisomer, has been reported to have 10% of the in vitro adrenergic-lipolytic activity of (−)-epinephrine and only 7% in vitro competitive binding a...
Gespeichert in:
| Veröffentlicht in: | Journal of pharmaceutical sciences 1986-01, Vol.75 (1), p.78-79 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 79 |
|---|---|
| container_issue | 1 |
| container_start_page | 78 |
| container_title | Journal of pharmaceutical sciences |
| container_volume | 75 |
| creator | Kowarski, Chana R. Liaou, Ming Yu Kowarsk, A. Avinoam |
| description | (−)-Epinephrine is a major component in the regulation of the physiological homeostasis of glucose levels in the blood. (+)-Epinephrine, a synthetic stereoisomer, has been reported to have 10% of the in vitro adrenergic-lipolytic activity of (−)-epinephrine and only 7% in vitro competitive binding activity to fat cells. The in vivo hypergly-cemic effects of the two stereoisomers were studied in 6 dogs using a continuous glucose monitor. The method allowed a direct comparison between the hyperglycemic effects of the two stereoisomers in each dog in the course of each test; therefore, the effect of individual variability of response was eliminated. Previous reports on the relative activity of the two stereoisomers were carried out only in vitro. The previous methods required interassay comparison. The present method is in vivo and uses intra-assay comparison. The hyperglycemic activity of (+)-epinephrine bitartrate was found to have 12.8% of the hyperglycemic activity of its natural (−)-stereoisomer. |
| doi_str_mv | 10.1002/jps.2600750118 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76761662</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354915470029</els_id><sourcerecordid>76761662</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3268-b708a91a0e1e436e93196cbc859d509d7845438a7f21833c984efd48b28e11fd3</originalsourceid><addsrcrecordid>eNqFkc9uEzEQhy1EVdLClRuSDwi1Qhv8Z-21jzQNbWkESBQqcbEc77i43exu7aSQN-iZR-RJMNooiAPi4jnM9xvb3yD0lJIxJYS9uu7TmElCKkEoVQ_QiApGCklo9RCNMsAKLkr9CO2ldE0IkUSIXbTLtVCa0hE6Omvx53DX4dN1D_GqWTtYBIen3oNb4s7jg5_3Pw4LbNsaH7w8LKZ9aKH_GvOJQ4uPu6v0GO142yR4sqn76NOb6cXktJi9PzmbvJ4VjjOpinlFlNXUEqBQcgmaUy3d3Cmha0F0XalSlFzZyjOqOHdaleDrUs2ZAkp9zffRi2FuH7vbFaSlWYTkoGlsC90qmUpWkkrJMjgeQBe7lCJ408ewsHFtKDG_pZkszfyRlgPPNpNX8wXUW3xjKfefb_o2Odv4aFsX0hZTitGsNWN6wL6FBtb_udS8_fDxrycUQzakJXzfZm28MbLilTCX707M5Jx-ubicCXOeeTXwkI3fBYgmuQCtgzrEvDlTd-Ffv_0FCUCkQw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76761662</pqid></control><display><type>article</type><title>In Vivo Hyperglycemic Effect of (−)- and (+)-Epinephrine in Dogs</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Kowarski, Chana R. ; Liaou, Ming Yu ; Kowarsk, A. Avinoam</creator><creatorcontrib>Kowarski, Chana R. ; Liaou, Ming Yu ; Kowarsk, A. Avinoam</creatorcontrib><description>(−)-Epinephrine is a major component in the regulation of the physiological homeostasis of glucose levels in the blood. (+)-Epinephrine, a synthetic stereoisomer, has been reported to have 10% of the in vitro adrenergic-lipolytic activity of (−)-epinephrine and only 7% in vitro competitive binding activity to fat cells. The in vivo hypergly-cemic effects of the two stereoisomers were studied in 6 dogs using a continuous glucose monitor. The method allowed a direct comparison between the hyperglycemic effects of the two stereoisomers in each dog in the course of each test; therefore, the effect of individual variability of response was eliminated. Previous reports on the relative activity of the two stereoisomers were carried out only in vitro. The previous methods required interassay comparison. The present method is in vivo and uses intra-assay comparison. The hyperglycemic activity of (+)-epinephrine bitartrate was found to have 12.8% of the hyperglycemic activity of its natural (−)-stereoisomer.</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1002/jps.2600750118</identifier><identifier>PMID: 3958911</identifier><identifier>CODEN: JPMSAE</identifier><language>eng</language><publisher>Washington: Elsevier Inc</publisher><subject>Animals ; Biological and medical sciences ; Blood Glucose - metabolism ; Dogs ; Epinephrine - pharmacology ; Female ; General and cellular metabolism. Vitamins ; Medical sciences ; Pharmacology. Drug treatments ; Stereoisomerism</subject><ispartof>Journal of pharmaceutical sciences, 1986-01, Vol.75 (1), p.78-79</ispartof><rights>1986 Wiley-Liss, Inc., A Wiley Company</rights><rights>Copyright © 1986 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1986 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3268-b708a91a0e1e436e93196cbc859d509d7845438a7f21833c984efd48b28e11fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjps.2600750118$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjps.2600750118$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,4010,27900,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8821055$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3958911$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kowarski, Chana R.</creatorcontrib><creatorcontrib>Liaou, Ming Yu</creatorcontrib><creatorcontrib>Kowarsk, A. Avinoam</creatorcontrib><title>In Vivo Hyperglycemic Effect of (−)- and (+)-Epinephrine in Dogs</title><title>Journal of pharmaceutical sciences</title><addtitle>J. Pharm. Sci</addtitle><description>(−)-Epinephrine is a major component in the regulation of the physiological homeostasis of glucose levels in the blood. (+)-Epinephrine, a synthetic stereoisomer, has been reported to have 10% of the in vitro adrenergic-lipolytic activity of (−)-epinephrine and only 7% in vitro competitive binding activity to fat cells. The in vivo hypergly-cemic effects of the two stereoisomers were studied in 6 dogs using a continuous glucose monitor. The method allowed a direct comparison between the hyperglycemic effects of the two stereoisomers in each dog in the course of each test; therefore, the effect of individual variability of response was eliminated. Previous reports on the relative activity of the two stereoisomers were carried out only in vitro. The previous methods required interassay comparison. The present method is in vivo and uses intra-assay comparison. The hyperglycemic activity of (+)-epinephrine bitartrate was found to have 12.8% of the hyperglycemic activity of its natural (−)-stereoisomer.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - metabolism</subject><subject>Dogs</subject><subject>Epinephrine - pharmacology</subject><subject>Female</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Stereoisomerism</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9uEzEQhy1EVdLClRuSDwi1Qhv8Z-21jzQNbWkESBQqcbEc77i43exu7aSQN-iZR-RJMNooiAPi4jnM9xvb3yD0lJIxJYS9uu7TmElCKkEoVQ_QiApGCklo9RCNMsAKLkr9CO2ldE0IkUSIXbTLtVCa0hE6Omvx53DX4dN1D_GqWTtYBIen3oNb4s7jg5_3Pw4LbNsaH7w8LKZ9aKH_GvOJQ4uPu6v0GO142yR4sqn76NOb6cXktJi9PzmbvJ4VjjOpinlFlNXUEqBQcgmaUy3d3Cmha0F0XalSlFzZyjOqOHdaleDrUs2ZAkp9zffRi2FuH7vbFaSlWYTkoGlsC90qmUpWkkrJMjgeQBe7lCJ408ewsHFtKDG_pZkszfyRlgPPNpNX8wXUW3xjKfefb_o2Odv4aFsX0hZTitGsNWN6wL6FBtb_udS8_fDxrycUQzakJXzfZm28MbLilTCX707M5Jx-ubicCXOeeTXwkI3fBYgmuQCtgzrEvDlTd-Ffv_0FCUCkQw</recordid><startdate>198601</startdate><enddate>198601</enddate><creator>Kowarski, Chana R.</creator><creator>Liaou, Ming Yu</creator><creator>Kowarsk, A. Avinoam</creator><general>Elsevier Inc</general><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><general>American Pharmaceutical Association</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198601</creationdate><title>In Vivo Hyperglycemic Effect of (−)- and (+)-Epinephrine in Dogs</title><author>Kowarski, Chana R. ; Liaou, Ming Yu ; Kowarsk, A. Avinoam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3268-b708a91a0e1e436e93196cbc859d509d7845438a7f21833c984efd48b28e11fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - metabolism</topic><topic>Dogs</topic><topic>Epinephrine - pharmacology</topic><topic>Female</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Stereoisomerism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kowarski, Chana R.</creatorcontrib><creatorcontrib>Liaou, Ming Yu</creatorcontrib><creatorcontrib>Kowarsk, A. Avinoam</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kowarski, Chana R.</au><au>Liaou, Ming Yu</au><au>Kowarsk, A. Avinoam</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Vivo Hyperglycemic Effect of (−)- and (+)-Epinephrine in Dogs</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J. Pharm. Sci</addtitle><date>1986-01</date><risdate>1986</risdate><volume>75</volume><issue>1</issue><spage>78</spage><epage>79</epage><pages>78-79</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><coden>JPMSAE</coden><abstract>(−)-Epinephrine is a major component in the regulation of the physiological homeostasis of glucose levels in the blood. (+)-Epinephrine, a synthetic stereoisomer, has been reported to have 10% of the in vitro adrenergic-lipolytic activity of (−)-epinephrine and only 7% in vitro competitive binding activity to fat cells. The in vivo hypergly-cemic effects of the two stereoisomers were studied in 6 dogs using a continuous glucose monitor. The method allowed a direct comparison between the hyperglycemic effects of the two stereoisomers in each dog in the course of each test; therefore, the effect of individual variability of response was eliminated. Previous reports on the relative activity of the two stereoisomers were carried out only in vitro. The previous methods required interassay comparison. The present method is in vivo and uses intra-assay comparison. The hyperglycemic activity of (+)-epinephrine bitartrate was found to have 12.8% of the hyperglycemic activity of its natural (−)-stereoisomer.</abstract><cop>Washington</cop><pub>Elsevier Inc</pub><pmid>3958911</pmid><doi>10.1002/jps.2600750118</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3549 |
| ispartof | Journal of pharmaceutical sciences, 1986-01, Vol.75 (1), p.78-79 |
| issn | 0022-3549 1520-6017 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76761662 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
| subjects | Animals Biological and medical sciences Blood Glucose - metabolism Dogs Epinephrine - pharmacology Female General and cellular metabolism. Vitamins Medical sciences Pharmacology. Drug treatments Stereoisomerism |
| title | In Vivo Hyperglycemic Effect of (−)- and (+)-Epinephrine in Dogs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T19%3A26%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Vivo%20Hyperglycemic%20Effect%20of%20(%E2%88%92)-%20and%20(+)-Epinephrine%20in%20Dogs&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Kowarski,%20Chana%20R.&rft.date=1986-01&rft.volume=75&rft.issue=1&rft.spage=78&rft.epage=79&rft.pages=78-79&rft.issn=0022-3549&rft.eissn=1520-6017&rft.coden=JPMSAE&rft_id=info:doi/10.1002/jps.2600750118&rft_dat=%3Cproquest_cross%3E76761662%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76761662&rft_id=info:pmid/3958911&rft_els_id=S0022354915470029&rfr_iscdi=true |